LeMaitre Vascular (LMAT) President David Roberts boosts holdings via option exercise

Rhea-AI Filing Summary

LeMaitre Vascular President and Director David B. Roberts reported exercising stock options and acquiring common shares of the company. On February 5, 2026, he exercised options for 2,672 shares at $37.29 and 7 shares at $48.60, receiving the same number of common shares.

Following these transactions, Roberts directly owned 24,930 shares of common stock. The option grants exercised were fully vested and exercisable, and after the transactions one option grant was fully used while another left 14,054 options outstanding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts David B

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Director

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		M		2,672(1)	A	$37.29	24,923	D
Common Stock	02/05/2026		M		7(1)	A	$48.6	24,930	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$37.29	02/05/2026		M			2,672	12/02/2020(2)	12/02/2027	Common Stock	2,672	$0	0	D
Stock Option (Right to Buy)	$48.6	02/05/2026		M			7	12/11/2021(2)	12/11/2028	Common Stock	7	$0	14,054	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. This option is fully vested and exercisable.

	/s/ Laurie A. Churchill, Attorney-in-fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LMAT’s David B. Roberts report on February 5, 2026?

David B. Roberts reported exercising stock options and acquiring LMAT common shares. He exercised options for 2,672 shares at $37.29 and 7 shares at $48.60, increasing his directly held common stock as disclosed in the Form 4 filing.

How many LeMaitre Vascular (LMAT) shares does David B. Roberts own after this Form 4?

After the reported transactions, David B. Roberts directly owns 24,930 shares of LeMaitre Vascular common stock. This reflects the addition of 2,672 and 7 shares acquired through option exercises disclosed in the Form 4 filed for the February 5, 2026 transactions.

What stock options did David B. Roberts exercise in the latest LMAT Form 4?

Roberts exercised two stock option grants, both fully vested and exercisable. One grant for 2,672 shares at $37.29 and another for 7 shares at $48.60 were converted into common stock, as detailed in Table II of the Form 4 filing.

How many LMAT stock options does David B. Roberts still hold after these exercises?

Following the February 5, 2026 exercises, one 2,672-share option grant was fully used, leaving zero options from that grant. Another grant remains with 14,054 derivative securities (stock options) still beneficially owned directly, according to the Form 4 disclosure.

What is the role of David B. Roberts at LeMaitre Vascular (LMAT) in this Form 4?

In this Form 4, David B. Roberts is identified as both a director and an officer of LeMaitre Vascular, serving as President and Director. The reported transactions involve his direct beneficial ownership of common stock and stock options in the company.